<DOC>
	<DOC>NCT02756819</DOC>
	<brief_summary>The purpose of this study is to estimate antihypertensive effect of azilsartan medoxomil (Edarbi®) therapy on blood pressure in participants with overweight or obesity in routine clinical practice of hypertension (HTN) treatment in the Russian Federation and in the Republic of Kazakhstan..</brief_summary>
	<brief_title>International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan</brief_title>
	<detailed_description>The drug being tested in this study is called azilsartan medoxomil. Azilsartan medoxomil is being tested to treat people who have hypertension. This study will look at the clinic systolic and diastolic blood pressure (SBP, DBP) in obese participants who will be prescribed with azilsartan medoxomil by physician. The study will enroll approximately 1916 patients. All participants will be asked to take azilsartan medoxomil as prescribed by their physician according to local SmPC. This multi-center trial will be conducted in the Russian Federation and the Republic of Kazakhstan. The overall duration of study for observation will be approximately 6 months. Participants will make multiple visits to the clinic as assigned by each physician according to their routine practice, in every 3 months.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>1. Male and female participants ≥ 18 years of age with hypertension (HTN) 12 grade. 2. Participants with: newly diagnosed arterial HTN or inadequately controlled previously prescribed monotherapy with ReninAngiotensinAldosterone System (RAAS) blocker or inadequately controlled previously prescribed combination therapy with RAAS blocker + diuretic or RAAS blocker + calcium antagonist. 3. The physician decides to prescribe Edarbi as monotherapy or as a part of combination therapy including diuretics or calcium antagonists; 4. Overweight or obesity of any degree (body mass index&gt; 25 kg/m^2); 5. Is capable of understanding the written informed consent, provides signed and written informed consent, and agrees to comply with protocol requirements. In case the participant is blind or unable to read, informed consent will also be witnessed. 1. Confirmed secondary HTN; 2. Contraindications for Edarbi of respective approved local summary of product characteristics (SmPC) of Edarbi; 3. Any reasons of medical and nonmedical character, which in the opinion of the physician can prevent participant participation in the study. 4. Is an employee or family member of the investigator or study site personnel. 5. Is currently participating in a clinical trial. Participation in noninterventional registries is permitted.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>